MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

40.98 -2.82

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

42.15

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+27.99% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-639K 3.2B
Eelmine avamishind	43.8
Eelmine sulgemishind	40.98

Uudiste sentiment

By Acuity

50%

190 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. jaan 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. jaan 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. jaan 2026, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- Update

8. jaan 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks

8. jaan 2026, 17:05 UTC

Omandamised, ülevõtmised, äriostud

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. jaan 2026, 16:43 UTC

Suurimad hinnamuutused turgudel

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. jaan 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. jaan 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. jaan 2026, 21:53 UTC

Tulu

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. jaan 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. jaan 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. jaan 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. jaan 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. jaan 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. jaan 2026, 17:48 UTC

Tulu

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. jaan 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. jaan 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. jaan 2026, 15:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Defends Its Hostile Bid for Warner -- Update

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

27.99% tõus

12 kuu keskmine prognoos

Keskmine 53.91 USD 27.99%

Kõrge 60 USD

Madal 44 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

190 / 372 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.